source
- Zymeworks CEO says $1 billion Theravance acquisition offers strong value despite recent setbacksZymeworks chief executive Kenneth Galbraith explained why the company believes its near-$1 billion purchase of Theravance makes strategic sense. He noted that Theravance has faced operational diff…
- Evommune's lead drug fails in chronic hives trial, shares tumble over 30%Evommune reported its first major trial readout since going public last year, focusing on its lead candidate for chronic spontaneous urticaria, a condition where patients experience recurring hives…